{"success":true,"data":{"pressRelease":{"id":"155225","rtpr_id":"nGNXrHCtp-20260929","ticker":"BBNX","exchange":"NASDAQ","all_tickers":["BBNX"],"title":"Beta Bionics to Announce Third Quarter 2026 Financial Results on October 27, 2026","author":"Globe Newswire","published_at":"2026-09-29T12:00:01.820Z","article_body":"IRVINE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq:\nBBNX), a pioneering leader in the development of advanced diabetes management\nsolutions, today announced that it plans to release its third quarter 2026\nfinancial results after the financial markets close on Tuesday, October 27,\n2026. Management will host a conference call and concurrent webcast on the\nsame day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the\ncompany’s third quarter 2026 performance.\n\nThe link to the webcast will be available on the Company’s website in the\n“Investors—Events & Presentations” section at\nhttps://investors.betabionics.com, and will be archived there for future\nreplay. To access the live call by phone, please use the following link, which\nwill provide you with dial-in details and a personal pin:\nhttps://register-conf.media-server.com/register/BIb765a5e68b554419b9df996402991220\n\nAbout Beta Bionics\n\nBeta Bionics, Inc. is a commercial-stage medical device company engaged in the\ndesign, development, and commercialization of innovative solutions to improve\nthe health and quality of life of insulin-requiring people with diabetes (PWD)\nby utilizing advanced adaptive closed-loop algorithms to simplify and improve\nthe treatment of their disease. Beta Bionics’ proprietary insulin dosing\nalgorithm is the first FDA-cleared algorithm that autonomously determines\nevery insulin dose and offers the potential to substantially improve overall\noutcomes across broad populations of PWD. To learn more, visit\nwww.betabionics.com.\n\nInvestor Relations:\nBlake Beber\nHead of Investor Relations\nir@betabionics.com\n\nMedia and Public Relations: \nFelicia Sanborn\nVice President of Marketing\nmedia@betabionics.com\n\nSource: Beta Bionics, Inc.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/88df4d95-789c-467a-8481-f67e19e1adfa)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXrHCtp-20260929","title":"Beta Bionics to Announce Third Quarter 2026 Financial Results on October 27, 2026","author":"Globe Newswire","ticker":"BBNX","created":"2026-09-29T12:00:01.820Z","tickers":["BBNX"],"exchange":"NASDAQ","article_body":"IRVINE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq:\nBBNX), a pioneering leader in the development of advanced diabetes management\nsolutions, today announced that it plans to release its third quarter 2026\nfinancial results after the financial markets close on Tuesday, October 27,\n2026. Management will host a conference call and concurrent webcast on the\nsame day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the\ncompany’s third quarter 2026 performance.\n\nThe link to the webcast will be available on the Company’s website in the\n“Investors—Events & Presentations” section at\nhttps://investors.betabionics.com, and will be archived there for future\nreplay. To access the live call by phone, please use the following link, which\nwill provide you with dial-in details and a personal pin:\nhttps://register-conf.media-server.com/register/BIb765a5e68b554419b9df996402991220\n\nAbout Beta Bionics\n\nBeta Bionics, Inc. is a commercial-stage medical device company engaged in the\ndesign, development, and commercialization of innovative solutions to improve\nthe health and quality of life of insulin-requiring people with diabetes (PWD)\nby utilizing advanced adaptive closed-loop algorithms to simplify and improve\nthe treatment of their disease. Beta Bionics’ proprietary insulin dosing\nalgorithm is the first FDA-cleared algorithm that autonomously determines\nevery insulin dose and offers the potential to substantially improve overall\noutcomes across broad populations of PWD. To learn more, visit\nwww.betabionics.com.\n\nInvestor Relations:\nBlake Beber\nHead of Investor Relations\nir@betabionics.com\n\nMedia and Public Relations: \nFelicia Sanborn\nVice President of Marketing\nmedia@betabionics.com\n\nSource: Beta Bionics, Inc.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/88df4d95-789c-467a-8481-f67e19e1adfa)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-29T12:00:01.865779366Z","server_sent_at_ms":1790683201865},"received_at":"2026-09-29T12:00:01.916Z","source_url":null},"analysis":{"id":"143954","press_release_id":"155225","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":[],"eventType":"earnings","narrative":"Beta Bionics will release third quarter 2026 financial results after market close on Tuesday, October 27, 2026.\n\nManagement will host a conference call and webcast the same day at 4:30 pm Eastern Time to review quarterly performance.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Calendar note only -- BBNX Q3 2026 earnings set for October 27 after the close."},"keyFigures":{},"quotedText":"","namedEntities":{"people":[{"name":"Blake Beber","role":"Head of Investor Relations"},{"name":"Felicia Sanborn","role":"Vice President of Marketing"}],"products":[],"companies":[{"name":"Beta Bionics, Inc.","ticker":"BBNX"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"This is a routine announcement of an upcoming earnings date and conference call; no financial results or new information are disclosed."},"tickerRelevance":{"others":[],"primary":"BBNX"},"globalImportance":8,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"earnings-date-announcement","issuerAuthored":true}},"event_type":"earnings","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Beta Bionics will release third quarter 2026 financial results after market close on Tuesday, October 27, 2026.\n\nManagement will host a conference call and webcast the same day at 4:30 pm Eastern Time to review quarterly performance.","key_figures":{},"named_entities":{"people":[{"name":"Blake Beber","role":"Head of Investor Relations"},{"name":"Felicia Sanborn","role":"Vice President of Marketing"}],"products":[],"companies":[{"name":"Beta Bionics, Inc.","ticker":"BBNX"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-29T12:00:17.378Z","global_importance":8,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap","eventGravity":"earnings-date-announcement","issuerAuthored":true}},"durationMs":4959,"modelName":"glm-5.3-flashx"}}